

H: (202)-341-8398 | sddxlilei@gmail.com

Professional Summary

- Al consultant, familiar with modern popular deep learning techniques with application to quant theory, drug discovery, and automation.
- Seasoned PhD biostatistician with extensive experience from both regulatory agencies and leading biotech
 pharmaceutical companies. Specializing in both clinical trial designs and applications to advanced biostatistical
 methods.
- Statistical project leader on moderate to large size projects varying from phase I to phase III with hands on submission experience.
- Outstanding Communication and Leadership Skills.

Professional Experience

Independent AI and Stats Consultant

06/2023 - Present

Statistical Project Leader, Deputy Director - Sanofi

06/2023 - 04/2025

- Vaccine: Leading several vaccine projects:
 - Project leader on periodontal disease vaccine study (translational study, phase I/II): I lead on the
 protocols and SAPs design, where novelly I apply multinomial logistic regression method for biomarkers
 analysis. Also, I use Bayesian decision by design framework to help team with the Go/No Go decisionmaking process.
 - Project leader on Acne vaccine project (two phase I/II studies): I lead on the protocols and SAPs design, where the Multiple Comparison Procedure Modeling (MCPMod) is proposed for both sample size determination and dose-finding. Also, I collaboratively perform daily statistical activities such as ESDR, DSUR.
 - Project Leader on phase III rabies vaccine: hands on experience on submissions to FDA and EMA (e.g., pre-BLA and BIMO preparation, ISE, ISS submission).
 - Study statistician on Expec project for Escherichia coli phase III study E.mbrace. This is a Bayesian group sequential design study, I mainly conduct efficacy and futility analysis using Bayesian method.
- Statistical Innovation Group: As statistical expert, I lead several statistical methodology developments:
 - Dose Finding method: Using the Multiple Comparison Procedure Modeling (MCPMod) framework,
 - Decision by Design (DxD) framework: we use Bayesian method to facilitate the GO/NO GO decisionmaking process from phase I/II towards phase III.
 - Develop the Group Sequential Design theory under the Binomial distribution with application to vaccines.
- Rare disease: Co-lead several phase III hemophilia studies: i) develop/validate efficacy results including the primary and key secondary analyses (e.g., ISE); ii) create and validate safety results and outputs (e.g., ISS); iii) work on new pivotal table shells/CSR including complex patient flowchart; iv) perform adhoc analysis to support requests from other teams identifying key patterns affecting efficacy endpoints.

Principal BioStatistician – Edwards Lifesciences

04/2022 - 04/2023

Lead Biostatistician on two early feasibility studies (i.e., phase I/II) of cardiovascular projects: i) Develop clinical trial statistical analysis plan (SAP), data specs, and statistical analysis for the early feasibility projects; ii) Lead the statistical data analysis with mixed modeling techniques and win ratio methods; iii) Co-lead the statistical analysis part for the publication paper "Left Atrial to Coronary Sinus Shunting for Treatment of Symptomatic Heart Failure" at JACC cardiovascular interventions journal; iv) Mentor junior level staff onboard and other biostatistics business

Mathematical Statistician - FDA/CDRH

- 09/2020 04/2022
- Leading reviewer of RWD/RWE submissions using propensity score methodology including the areas of breast reconstruction, cervical artificial disc, etc.
- Review and provide professional statistical memo for therapeutic and diagnostic medical devices such as general surgical and orthopedic devices, in invo and in vitro diagnostic devices, etc.
- Hands on experience with all types of medical device submissions such as pre-submissions, IDEs, 510(k)s, De Novo, and PMA.

Graduate Teaching Assistant, George Mason University

08/2018 to 05/2020

Education and Training

Ph.D. in Statistics, George Mason University

05/2020

· Thesis: Generalize EM algorithm with application to healthcare data

MS in Statistics, George Washington University

05/2015

BS in Mathematics, Shandong University (China)

06/2013

Statistical Expertise

- MMRM, Group Sequential Design, Bayesian Design, Adaptive Design, Real World Evidence, doseresponse finding, Win Ratio Approach, Go/No Go Decision-making, MCPMod, Machine Learning on biostatistics, Causal Inference, Permutation Test.
- Statistical Software: Substantive experience on SAS, R, Python

Publications

- Vidyashankar, A.N., **Li, L.** (2019) "Ancestral Inference for Branching Processes in Random Environments and an Application to Polymerase Chain Reaction". *Stochastic Models*, 1-20, Taylor & Francis
- Li, L., Vidyashankar, A.N., Diao, G., Ahmad, E. (2019) "Robust Inference after Random Projections via Hellinger Distance for Location-scale Family". *Entropy*, 21, 348
- Li, L., Vidyashankar, A.N. (2019) "Divergence Methods for Models with Latent Structure: Theory and Algorithms". Pre-print version
- Li, L., Vidyashankar, A.N., Clark C., Doyle, L.J. (2019) "Statistical Framework for Measuring and Assessing Security Risk in Healthcare Databases". *Pre-print version*

Selected Professional Presentations

- Joint Statistical Meeting, Denver, CO 07/2019
 Presentation titled "Divergence Based Inference for High Dimensional GLMM"
- ICORS-LACSC Robust Statistics Conference, Guayaquil, Ecuador 05/2019
 Presentation titled "Divergence Methods for Models with Latent Structure: Theory and Algorithms"
- Joint Statistical Meeting, Vancouver, Canada 07/2018
 Presentation titled "Privacy Analytics for Healthcare Data in Social Media via Divergence Techniques"
- Joint Statistical Meeting, Baltimore, MD 07/2017
 Presentation titled "Robust Estimate of Re-identication Risk In Complex Healthcare Data"

Selected Awards

Herculean Team Award Finalists, Edwards Lifesciences

Mar 2023

• Innovative Study Design Award Finalists, Edwards Lifesciences

Mar 2023

• Operational Excellence Award Finalists, Edwards Lifesciences

Mar 2023

• Outstanding Graduate Student, Washington Statistical Society

May 2017